US FDA audited the manufacturing plant from April 5 – 12, 2018
Zydus Hospira Oncology, a 50: 50 joint venture company between Zydus Cadila and Hospira, USA (now part Of Pfizer Group) has received an Establishment Inspection Report (EIR) from the US FDA which concluded that the inspection is closed and States that the inspection classification of this facility is ‘Voluntary Action Indicated’ (VAI). The manufacturing plant had completed the US FDA audit from 5th to 12th April 2018.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 22,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
Comments are closed.